Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
Personalis, Duke University, Olink Collaborate on Immunotherapy Markers in Gastric Cancer
They plan to study the genomic, transcriptomic, and proteomic responses of gastroesophageal tumors following treatment with Merck's Keytruda.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
FDA Approves Foundation Medicine Test as CDx for Merck's Keytruda to Identify MSI-H Solid Tumors
The FoundationOne CDx test can now be used as a companion diagnostic for the drug to identify patients with solid tumors that have high microsatellite instability.